Sonnet BioTherapeutics Holdings Inc.

About Sonnet BioTherapeutics Holdings Inc.

Sonnet BioTherapeutics, Inc. is a biotechnology company focused on developing targeted immuno-oncology drugs using their proprietary FHAB™ (Fully Human Albumin-Binding) technology. Their mission is to create innovative biologic drugs that transform 'cold' tumors into 'hot' ones, enhancing treatment efficacy through single- or bi-specific mechanisms.

Products & Services

FHAB™ Technology Platform:A platform utilizing a fully human single-chain antibody fragment that binds to human serum albumin for targeted delivery of cytokine payloads to tumors, enhancing penetration, retention, and local activation.

SON-1010:A clinical-stage cytokine-derived therapeutic candidate in the company's pipeline.

Specialties

Immuno-Oncology Cytokine Biology Targeted Biologic Drugs Drug Discovery and Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering and Concurrent Private Placement T: - FT: Registered Direct Offering and Concurrent Private Placement	A: 3900000 MR: - FA: $3.9 million FAN: 3900000	D: 2024-12-09 FD: 2024-12-09	2 investors
2	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 5000000 MR: - FA: $5.0 million FAN: 5000000	D: 2024-11-06 FD: 2024-11-06	1 investors
3	RT: Non-Dilutive Funding T: - FT: Non-Dilutive Funding	A: 795000 MR: - FA: up to $0.795 million FAN: 795000	D: 2024-10-04 FD: 2024-10-04	-
4	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 3400000 MR: - FA: $3.4 million FAN: 3400000	D: 2024-06-20 FD: 2024-06-20	-
5	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 4550000 MR: - FA: $4.55 million FAN: 4550000	D: 2023-10-25 FD: 2023-10-25	3 investors
6	RT: Registered Direct Offering and Concurrent Private Placement T: - FT: Registered Direct Offering and Concurrent Private Placement	A: 2250000 MR: - FA: $2.25 million FAN: 2250000	D: 2023-06-28 FD: 2023-06-28	1 investors
7	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 15000000 MR: - FA: $15.0 million FAN: 15000000	D: 2023-02-08 FD: 2023-02-08	2 investors

Registered Direct Offering and Concurrent Private Placement Latest

2024-12-09

$3.9M

2 investors (Pro only)

Underwritten Public Offering 2024-11-06

$5.0M

Non-Dilutive Funding 2024-10-04

$795K

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Pankaj Mohan

Founder, CEO & Chairman

A

Albert Dyrness

Board Member

N

Nailesh Bhatt

Board Member

R

Raghu Rao

Interim Chief Executive Officer

D

Donald Griffith

Chief Financial Officer

L

Lori McNeill

Board Member

View 7 more team members with Pro

Unlock Full Team Directory

Recent News